跳至主要内容
临床试验/JPRN-jRCT2080225142
JPRN-jRCT2080225142已完成3 期

Multicenter, Adaptive, Randomized, Placebo-Controlled, Comparative Study to Evaluate the Efficacy and Safety of Favipiravir in Patients with COVID-19 Non-Severe Pneumonia

FUJIFILM Toyama Chemical Co., Ltd.0 个研究点目标入组 96 人开始时间: 2020年3月27日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
96

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 74age old(—)
性别
All

入选标准

  • 1 Age: 20 to 74 years inclusive
  • 2.Sex: No restriction
  • 3 Out patient/hospitalization: Hospitalization
  • 4 Laboratory (RT-PCR) confirmed infection with SARS-CoV-2.
  • 5 Lung involvement confirmed with chest imaging
  • 6 Patients with fever of 37.5 degrees Celsius or more
  • 7 Have a negative pregnancy test before study treatment

排除标准

  • 1 Ten days or more have passed since the fever (37.5 degrees Celsius or more) started.
  • 2 Patients who are pregnant or may be pregnant
  • 3 Patients with severe hepatic or renal impairment

研究者

相似试验